Search

Author/Creator Yalamanchili, K.

1. 172P Phase I study of JTX-8064, a LILRB2 (ILT4) inhibitor, as monotherapy and combination with pimivalimab (pimi), a PD-1 inhibitor (PD-1i), in patients (pts) with advanced solid tumors. (December 2022)

Authors:
Papadopoulos, K.; Li, T.; Lakhani, N.; Powderly, J.; George, T.; Teoh, D.G.K.; Kilari, D.; Giaccone, G.; Sanborn, R.E.; Ghamande, S.; LoRusso, P.; Gibney, G.; Ma, V.T-L.; Yalamanchili, K.; Brown, J.; Mota, N.; Tasillo Kadra, C.; Umiker, B.; Xiao, X.; Trehu, E.
Journal:
Immuno-oncology technology
Issue:
Volume 16(2022)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search